MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

MicroRNAs (miRNAs) are small RNA molecules that regulate genes and are involved in various biological processes, including cancer development. Researchers have been exploring the potential of miRNAs as therapeutic agents in cancer treatment. Specifically, targeting the mammalian target of the rapamy...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2024-07, Vol.24 (1), p.233-15, Article 233
Main Authors: Taeb, Shahram, Rostamzadeh, Davoud, Amini, Seyed Mohammad, Rahmati, Mohammad, Eftekhari, Mohammad, Safari, Arash, Najafi, Masoud
Format: Article
Language:English
Subjects:
Angiogenesis
Cancer therapies
Cell growth
Cell proliferation
Clinical trials
Homeostasis
Immune response
Kinases
MicroRNAs
miRNA
mTOR
Mutation
Radiation therapy
Radiosensitivity
Radiotherapy
Rapamycin
Review
Therapeutic agents
TOR protein
Tumorigenesis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNAs (miRNAs) are small RNA molecules that regulate genes and are involved in various biological processes, including cancer development. Researchers have been exploring the potential of miRNAs as therapeutic agents in cancer treatment. Specifically, targeting the mammalian target of the rapamycin (mTOR) pathway with miRNAs has shown promise in improving the effectiveness of radiotherapy (RT), a common cancer treatment. This review provides an overview of the current understanding of miRNAs targeting mTOR as therapeutic agents to enhance RT outcomes in cancer patients. It emphasizes the importance of understanding the specific miRNAs that target mTOR and their impact on radiosensitivity for personalized cancer treatment approaches. The review also discusses the role of mTOR in cell homeostasis, cell proliferation, and immune response, as well as its association with oncogenesis. It highlights the different ways in which miRNAs can potentially affect the mTOR pathway and their implications in immune-related diseases. Preclinical findings suggest that combining mTOR modulators with RT can inhibit tumor growth through anti-angiogenic and anti-vascular effects, but further research and clinical trials are needed to validate the efficacy and safety of using miRNAs targeting mTOR as therapeutic agents in combination with RT. Overall, this review provides a comprehensive understanding of the potential of miRNAs targeting mTOR to enhance RT efficacy in cancer treatment and emphasizes the need for further research to translate these findings into improved clinical outcomes.
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-024-03420-3